Insight into the inhibitory activity of mangiferin and Silybin against HER2 and EGFR using theoretical and experimental approaches.

ABSTRACT: Despite the advances made in diagnosing and treating breast cancer, it continues to pose a significant threat to women's health. High-risk mutations can lead to high resistance to current treatments and poor prognosis. Therefore, new treatment strategies are needed. Mangiferin and silybin, two natural substances obtained from plants, have demonstrated encouraging results as anticancer drugs. This study investigated the activity of these compounds against two therapeutic targets, human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR). We assessed the binding affinity and stability of these compounds with the active sites of wild-type and mutated HER2 and EGFR by using computational screening techniques, namely molecular docking, density functional theory

SUBMITTER: Alvarado-Lozano JE 

PROVIDER: S-EPMC11906813 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature